Combined therapies for Duchenne muscular dystrophy to optimize treatment efficacy

Vista sencilla de ítem
dc.contributor.authorCordova, G.
dc.contributor.authorNegroni, E.
dc.contributor.authorCabello-Verrugio, C.
dc.contributor.authorMouly, V.
dc.contributor.authorTrollet, C.
dc.date.accessioned2019-03-25T18:40:59Z
dc.date.available2019-03-25T18:40:59Z
dc.date.issued2018-04
dc.descriptionIndexación: Scopus.es_ES
dc.description.abstractDuchene Muscular Dystrophy (DMD) is the most frequent muscular dystrophy and one of the most severe due to the absence of the dystrophin protein. Typical pathological features include muscle weakness, muscle wasting, degeneration, and inflammation. At advanced stages DMD muscles present exacerbated extracellular matrix and fat accumulation. Recent progress in therapeutic approaches has allowed new strategies to be investigated, including pharmacological, gene-based and cell-based therapies. Gene and cell-based therapies are still limited by poor targeting and low efficiency in fibrotic dystrophic muscle, therefore it is increasingly evident that future treatments will have to include "combined therapies" to reach maximal efficiency. The scope of this mini-review is to provide an overview of the current literature on such combined therapies for DMD. By "combined therapies" we mean those that include both a therapy to correct the genetic defect and an additional one to address one of the secondary pathological features of the disease. In this mini-review, we will not provide a comprehensive view of the literature on therapies for DMD, since many such reviews already exist, but we will focus on the characteristics, efficiency, and potential of such combined therapeutic strategies that have been described so far for DMD. © 2018 Cordova, Negroni, Cabello-Verrugio, Mouly and Trollet.es_ES
dc.description.urihttps://www.frontiersin.org/articles/10.3389/fgene.2018.00114/full
dc.identifier.citationFrontiers in Genetics, 9(APR), art. no. 114es_ES
dc.identifier.issn1664-8021
dc.identifier.otherhttps://doi.org/10.3389/fgene.2018.00114
dc.identifier.urihttp://repositorio.unab.cl/xmlui/handle/ria/8278
dc.language.isoenes_ES
dc.publisherFrontiers Mediaes_ES
dc.subjectAtrophyes_ES
dc.subjectCell therapyes_ES
dc.subjectDuchenne muscular dystrophyes_ES
dc.subjectDystrophines_ES
dc.subjectFibrosises_ES
dc.subjectGene therapyes_ES
dc.subjectInflammationes_ES
dc.subjectMusclees_ES
dc.titleCombined therapies for Duchenne muscular dystrophy to optimize treatment efficacyes_ES
dc.typeArtículoes_ES
Archivos
Bloque original
Mostrando 1 - 1 de 1
Miniatura
Nombre:
Cordova_Combined_Therapies.pdf
Tamaño:
782.26 KB
Formato:
Adobe Portable Document Format
Descripción:
TEXTO COMPLETO EN INGLES
Descargar
Bloque de licencias
Mostrando 1 - 1 de 1
No hay miniatura disponible
Nombre:
license.txt
Tamaño:
1.71 KB
Formato:
Item-specific license agreed upon to submission
Descripción:
Descargar
Colecciones
Fac.CV - Artículos de Revista